Wegovy and GLP-1s for Fatty Liver: What the Trials Show

TL;DR

• Semaglutide 2.4 mg (Wegovy) is approved for adults with MASH and moderate to advanced scarring (F2–F3) but not cirrhosis: by the FDA since August 15, 2025 (accelerated approval), and conditionally in the EU since March 26, 2026 under the name Kayshild.
• In the ESSENCE trial, 62.9% on semaglutide had resolution of steatohepatitis without worse scarring vs 34.3% on placebo, and 36.8% vs 22.4% had improved scarring, at 72 weeks. Weight fell by an average of 10.5% vs 2.0%.
• It’s an addition to diet and exercise, not a replacement. It isn’t approved for simple fatty liver, and the long-term outcome data are still to come.

Wegovy (semaglutide) is the first GLP-1 medicine approved for fatty liver, but only for a specific group: adults with MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) and moderate to advanced liver scarring, without cirrhosis. In the main trial it cleared liver inflammation in most people and improved scarring in more than a third, and the approval comes with the expectation that you’ll also change what you eat and move more.

This guide explains what GLP-1 drugs are, what the ESSENCE trial found and didn’t find, where the medicine is approved, who it’s for and what the label and guidelines say about diet. It sits alongside our guides on resmetirom, the other approved MASH medicine, and how to reverse fatty liver.

What Is Semaglutide, and How Might It Help the Liver?

Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone (glucagon-like peptide 1) that helps regulate blood sugar and appetite. It’s given as a once-weekly injection. Wegovy is the brand used at a 2.4 mg dose for weight management; the same dose was tested in the liver trial.

The exact way it helps the liver is still being worked out. Weight loss is likely a large part of it, since weight loss is the intervention most strongly linked to improvement in liver fat, inflammation and scarring. Whether it has additional direct effects on the liver is less settled, so I’ll stick to what trials measured rather than speculate.

What Did the ESSENCE Trial Find?

ESSENCE is a phase 3, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2025, funded by Novo Nordisk. It enrolled 1,197 people with biopsy-defined MASH and fibrosis stage 2 or 3, who received once-weekly semaglutide 2.4 mg or placebo (2 to 1) for a planned 240 weeks. The paper reported a planned interim analysis at week 72 in the first 800 patients (part 1).

Outcome at week 72	Semaglutide	Placebo	Difference
MASH resolved, no worsening of fibrosis	62.9%	34.3%	28.7 points
Fibrosis improved, no worsening of MASH	36.8%	22.4%	14.4 points
Both together	32.7%	16.1%	16.5 points
Average change in body weight	-10.5%	-2.0%	-8.5 points

Numbers are from the part 1 analysis of 534 people on semaglutide and 266 on placebo. Gastrointestinal adverse events were more common with semaglutide.

Reading it plainly:

• Inflammation responded well. Roughly six in ten people on the drug had their steatohepatitis resolve, versus about one in three on placebo.
• Scarring improved in a minority. About 37% had improvement in fibrosis on the drug, but 22% did on placebo too. The extra benefit attributable to the drug was around 14 percentage points. That is a meaningful but modest effect.
• Weight loss was substantial. An average 10.5% weight loss is in the range where the guidelines say fibrosis can improve, so some of the effect likely travels with the weight change.
• The placebo group also improved. Fibrosis improved in more than one in five people on placebo, which is exactly why trials include a placebo group: it shows how much change happens anyway.

What Doesn’t the Trial Show Yet?

• Long-term outcomes. The 72-week readout used biopsy results, which are surrogate markers. The trial is designed to run for 240 weeks to measure real outcomes such as progression to cirrhosis, but those results aren’t in yet. The EMA’s conditional approval says the same: the benefit data rest on biopsy results, not on hard outcomes such as transplantation or survival, and the company must submit more results.
• People without significant scarring. ESSENCE enrolled F2–F3 only. It says nothing about F0–F1 or about cirrhosis.
• Who loses most. Average results hide a range. Some people respond a lot and some barely at all.

An earlier, smaller trial described in the AASLD 2023 guidance showed the same split: a phase 2 trial of 320 people with NASH (daily semaglutide, 72 weeks) found NASH resolution in 59% at the highest dose (0.4 mg) vs 17% on placebo, but there was no statistically significant reduction in fibrosis compared with placebo. ESSENCE is bigger and longer, and it did show a fibrosis benefit.

Is Wegovy Approved for Fatty Liver?

Yes, for the specific group, in the US and the EU.

Region	Status	Date	Who it’s for
United States (FDA)	Accelerated approval for Wegovy (semaglutide 2.4 mg)	August 15, 2025	Adults with noncirrhotic MASH and moderate to advanced fibrosis, with a reduced-calorie diet and increased physical activity
European Union (EC/EMA)	Conditional marketing authorization as Kayshild (semaglutide)	March 26, 2026 (CHMP positive opinion January 29, 2026)	Adults with non-cirrhotic MASH and moderate to advanced fibrosis (F2–F3), with diet and exercise

“Accelerated” and “conditional” mean the approval was granted on interim biopsy data, and the company has to confirm the benefit with the ongoing trial. The AASLD published updated guidance on using semaglutide for MASH in November 2025. Press coverage of the guidance (we could not access the full text) describes it as favoring non-invasive tests over biopsy to identify moderate-to-advanced fibrosis, stressing the need to exclude cirrhosis first, and calling lifestyle modification the cornerstone alongside the drug. Read the full guidance, or ask your hepatologist, for the specifics.

Other countries have their own regulators and timelines, so check with your doctor about what applies where you live.

Who Is the MASH Indication For?

In practice, the approval describes someone who:

1. has MASH, meaning inflammation as well as fat;
2. has moderate to advanced fibrosis (F2 or F3), usually estimated by FIB-4 and FibroScan rather than biopsy; and
3. does not have cirrhosis.

This is the same group for which the European guideline says resmetirom should be considered. Our liver fibrosis stages guide explains F2 and F3 and how they’re measured. If your FIB-4 or FibroScan suggests significant scarring, ask whether you should see a hepatologist. A person with simple fatty liver and no scarring is not the target, and for that person the main tools remain lifestyle change and treating blood sugar, blood pressure and cholesterol.

What If You Take a GLP-1 for Diabetes or Weight and Have Fatty Liver?

You may benefit even without the MASH indication, and the liver is not a reason to avoid them. The 2024 European guideline, which was written before semaglutide’s MASH approval, says GLP-1 receptor agonists are safe to use in MASH, including compensated cirrhosis, and recommends incretin-based therapies (such as semaglutide or tirzepatide) for type 2 diabetes or obesity if indicated. At that time it stated that GLP-1 receptor agonists could not yet be recommended as MASH-targeted therapies, which is the part that changed when ESSENCE reported.

The guideline mentions a small randomized trial in 71 people with cirrhosis in which semaglutide 2.4 mg weekly was well tolerated and improved fat in the liver. It’s a safety signal, not a treatment indication for cirrhosis, and no MASH-targeted drug is currently recommended for the cirrhotic stage.

What About Tirzepatide and Other GLP-1 Drugs?

Tirzepatide (Mounjaro, Zepbound) acts on two gut hormone pathways (GLP-1 and GIP). A phase 2 trial in people with MASH and moderate to advanced scarring, published in the New England Journal of Medicine in 2024, reported higher rates of MASH resolution than placebo. The European guideline notes that histology data for the newer dual and triple agonists were not yet available when it was written. I couldn’t find an approval of tirzepatide specifically for MASH, and larger trials are ongoing, so talk to your doctor about where things stand. Evidence for GLP-1 drugs in lean people with fatty liver is also limited; see lean fatty liver.

What Does It Mean for Your Diet?

The approval is conditional on diet and activity, and the trial’s weight loss is the reason it works at all. Here’s how to think about food on a GLP-1:

• You’ll probably eat less, so what you eat counts more. With a smaller appetite, there’s less room for sugary drinks, refined starch and ultra-processed snacks. Our guide to best foods for fatty liver and the fatty liver diet guide cover the pattern guidelines favor: Mediterranean-style, plant-forward, low in added sugar.
• Expect GI side effects, and adjust. The most common side effects are gastrointestinal. Smaller meals and less greasy, fried food are the usual first moves; your prescriber can advise on dose changes.
• Don’t rely on the drug and skip the habits. The Wegovy indication is for use with a reduced-calorie diet and more physical activity, and the AASLD guidance is reported to call lifestyle the cornerstone.
• Keep protein and strength training in mind. Weight loss from any cause can include some muscle. Ask your care team about protein and resistance exercise, especially if you are older or have other conditions.
• Aim for steady loss. NIDDK notes that doctors recommend losing weight gradually, because rapid weight loss and malnutrition can make liver disease worse.
• Alcohol: with significant fibrosis (F2 and above) or cirrhosis the advice is none. See alcohol and fatty liver.

An app like Liverly can score meals for the liver, which is handy when your portions are changing.

Questions to Ask Your Doctor

1. What is my fibrosis stage, and how confident are we?
2. Am I a candidate for semaglutide, resmetirom, or neither?
3. How would my other medicines and conditions (diabetes, gallbladder, kidney) affect this?
4. What should I eat, and how should I handle side effects?
5. How will we know it’s working, and when do we recheck FIB-4 or FibroScan?

The Bottom Line

Semaglutide 2.4 mg is the first GLP-1 with a liver indication: approved by the FDA (August 2025) and conditionally in the EU as Kayshild (March 2026) for adults with MASH and F2–F3 scarring but no cirrhosis. In the ESSENCE trial, 62.9% had MASH resolve without worse scarring vs 34.3% on placebo, and 36.8% had better scarring vs 22.4%, at 72 weeks, with an average weight loss of 10.5%. It is not a cure, it isn’t approved for simple fatty liver, long-term outcomes are pending, and it works alongside food and activity changes. If you think you might qualify, start with your FIB-4 and FibroScan, and take the question to a hepatologist.

Sources

• Sanyal et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE; New England Journal of Medicine 2025)
• Novo Nordisk: Wegovy approved by FDA for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (August 15, 2025)
• European Medicines Agency: Kayshild (semaglutide)
• NIDDK: Treatment for MASLD and MASH (gradual weight loss)
• AASLD: Update to MASLD Practice Guidance (semaglutide for MASH, November 2025)
• EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD (Obesity Facts 2024)
• AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (Rinella et al., Hepatology 2023)

This article is for informational purposes only and is not medical advice. Talk to your doctor or hepatologist about your specific situation.